|
|
 Previous Article | Table of Contents | Next Article 
Treatment of Polycythemia Vera: The Use of Hydroxyurea and Pipobroman in 292 Patients Under the Age of 65 Years
Yves Najean and
Jean-Didier Rain for the French Polycythemia Study Group
From the Department of Nuclear Medicine, Hôpital Saint-Louis, Paris, France.
Nonradiomimetic drugs, hydroxyurea (HU) and pipobroman (Pi), were administred to relatively young subjects with polycythemia vera (PV) in an attempt to decrease the leukemogenic risk observed in patients treated with 32P. Clinical safety, hematological efficacy, risk of carcinoma or leukemia, and frequency of progression to myelofibrosis have not yet been defined in long-term studies, and no comparative studies of HU and Pi have been conducted. Since 1980, 292 patients with PV diagnosed before the age of 65 years were randomized to receive treatment with HU (25 mg/kg/d, followed by low-dose maintenance) or Pi (1.2 mg/kg/d, followed by low-dose maintenance). Patients were followed until death or until May 1997. Drug tolerance was often poor; leg ulcers and buccal aphthous ulcers (with HU) and gastric pain and diarrhea (with Pi) sometimes required treatment change, mainly in the HU arm. Hematological stability, especially in terms of platelet count, was very often insufficient with HU (45% of cases), but the risk of thrombo-embolic event was similar in both arms. Actuarial survival was similar in the two arms and shorter than that of the reference population. The risk of leukemia was approximately 10% at the 13th year, with no significant difference between the two arms. The risk of carcinoma (when excluding the skin cancers) was similar in both groups. There was a high risk of progression to myelofibrosis in the patients treated by HU, which was significantly higher than with Pi.
Blood, Vol. 90 No. 9 (November 1), 1997:
pp. 3370-3377
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. L. Spivak and R. T. Silver
The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal
Blood,
July 15, 2008;
112(2):
231 - 239.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Lanzkron, J. J. Strouse, R. Wilson, M. C. Beach, C. Haywood, H. Park, C. Witkop, E. B. Bass, and J. B. Segal
Systematic Review: Hydroxyurea for the Treatment of Adults with Sickle Cell Disease
Ann Intern Med,
June 17, 2008;
148(12):
939 - 955.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi
Management of Myeloproliferative Neoplasms and the Promise of Targeted Therapy
ASCO Educational Book,
January 1, 2008;
2008(1):
346 - 348.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Finazzi and T. Barbui
How I treat patients with polycythemia vera
Blood,
June 15, 2007;
109(12):
5104 - 5111.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Burkitt and A. Raafat
Nitric oxide generation from hydroxyurea: significance and implications for leukemogenesis in the management of myeloproliferative disorders
Blood,
March 15, 2006;
107(6):
2219 - 2222.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-S. Chim, Y.-L. Kwong, A. K.-W. Lie, S.-K. Ma, C.-C. Chan, L.-G. Wong, B. C. San Kho, H.-K. Lee, J. P.-Y. Sim, C.-H. Chan, et al.
Long-term Outcome of 231 Patients With Essential Thrombocythemia: Prognostic Factors for Thrombosis, Bleeding, Myelofibrosis, and Leukemia
Arch Intern Med,
December 12, 2005;
165(22):
2651 - 2658.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Finazzi, V. Caruso, R. Marchioli, G. Capnist, T. Chisesi, C. Finelli, L. Gugliotta, R. Landolfi, J. Kutti, H. Gisslinger, et al.
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study
Blood,
April 1, 2005;
105(7):
2664 - 2670.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Campbell and A. R. Green
Management of Polycythemia Vera and Essential Thrombocythemia
Hematology,
January 1, 2005;
2005(1):
201 - 208.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Steinberg, F. Barton, O. Castro, C. H. Pegelow, S. K. Ballas, A. Kutlar, E. Orringer, R. Bellevue, N. Olivieri, J. Eckman, et al.
Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia: Risks and Benefits Up to 9 Years of Treatment
JAMA,
April 2, 2003;
289(13):
1645 - 1651.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Spivak, G. Barosi, G. Tognoni, T. Barbui, G. Finazzi, R. Marchioli, and M. Marchetti
Chronic Myeloproliferative Disorders
Hematology,
January 1, 2003;
2003(1):
200 - 224.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Spivak
Polycythemia vera: myths, mechanisms, and management
Blood,
December 15, 2002;
100(13):
4272 - 4290.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. de Montalembert and S. C. Davies
Is hydroxyurea leukemogenic in children with sickle cell disease?
Blood,
November 1, 2001;
98(9):
2878 - 2879.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-I. Park, H.-S. Choi, J.-S. Jeong, J.-Y. Han, and I.-H. Kim
Involvement of p38 Kinase in Hydroxyurea-induced Differentiation of K562 Cells
Cell Growth Differ.,
September 1, 2001;
12(9):
481 - 486.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Chaine, M.-G. Neonato, R. Girot, and S. Aractingi
Cutaneous Adverse Reactions to Hydroxyurea in Patients With Sickle Cell Disease
Arch Dermatol,
April 1, 2001;
137(4):
467 - 470.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. N. Hanft, S. R. Fruchtman, C. V. Pickens, W. F. Rosse, T. A. Howard, and R. E. Ware
Acquired DNA mutations associated with in vivo hydroxyurea exposure
Blood,
June 1, 2000;
95(11):
3589 - 3593.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. C. Pearson, M. Messinezy, N. Westwood, A. R. Green, A. J. Bench, A. R. Green, B. J.P. Huntly, E. P. Nacheva, T. Barbui, and G. Finazzi
A Polycythemia Vera Update: Diagnosis, Pathobiology, and Treatment
Hematology,
January 1, 2000;
2000(1):
51 - 68.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M de Montalembert, P Begue, F Bernaudin, I Thuret, D Bachir, and M Micheau
Preliminary report of a toxicity study of hydroxyurea in sickle cell disease
Arch. Dis. Child.,
November 1, 1999;
81(5):
437 - 439.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T.C. Pearson, A.R. Green, G. Harrisoni;, and Y. Najean
Leukemic Transformation in Polycythemia Vera
Blood,
September 1, 1998;
92(5):
1837 - 1838.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Sterkers, C. Preudhomme, J.-L. Lai, J.-L. Demory, M.-T. Caulier, E. Wattel, D. Bordessoule, F. Bauters, and P. Fenaux
Acute Myeloid Leukemia and Myelodysplastic Syndromes Following Essential Thrombocythemia Treated With Hydroxyurea: High Proportion of Cases With 17p Deletion
Blood,
January 15, 1998;
91(2):
616 - 622.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
